Register for our nTMS Brain Mapping Workshop at ELGGN 2026!
Friday, 24th April | Mid-Day 1 h Session | Exact time TBA
At the 18th European Low Grade Glioma Meeting in Montpellier, France.
The workshop is divided into two sessions - motor mapping and language mapping.
Participants will be split into two equal-sized groups and after half an hour, groups switch. So you will have the opportunity two learn about both motor and language mapping:
Session "motor mapping" (30 mins)
At the 18th European Low Grade Glioma Meeting in Montpellier, France.
The workshop is divided into two sessions - motor mapping and language mapping.
Participants will be split into two equal-sized groups and after half an hour, groups switch. So you will have the opportunity two learn about both motor and language mapping:
Session "motor mapping" (30 mins)
- Introduction to nTMS pre-procedural motor mapping
- Hands-on time to practice motor mapping, guided by an experienced operator
- See how coil positioning, tilt and rotation influence stimulation intensity
- Learn why navigating the coil in real-time is crucial for accurate results
Session "language mapping" (30 mins)
- Introduction to nTMS language mapping
- Learn which types of speech errors you might see
- Hear how nTMS motor and language mapping data can then be imported into pre-operative planning software to support awake mapping in the OR
Note! Capacity is limited to 20 participants, on a first-come first-serve basis. If you are interested, we recommend you to sign-up as soon as possible, and we will have a waiting list, in case of cancellations.
If you have any questions beforehand, please feel free to reach out to: info@nexstim.com.
If you are interested in Nexstim navigated TMS and want to learn a little more about it beforehand, we recommend having a look at talks by experienced nTMS users here. See you in Montpellier!
If you are interested in Nexstim navigated TMS and want to learn a little more about it beforehand, we recommend having a look at talks by experienced nTMS users here. See you in Montpellier!
Intended purpose & Indications for use:
Pre-procedural mapping (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for localization and assessment of the motor cortex and motor tract integrity for pre-procedural planning purposes. NBS 6 is intended to be used for localization and assessment of cortical areas of speech function for pre-procedural planning purposes.
Indications for use: NBS 6 is indicated for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus. NBS 6 provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. NBS 6 is indicated for noninvasive localizations of cortical areas that do not contain essential speech function. NBS 6 provides information that may be used in pre-surgical planning in patients undergoing brain surgery. Intraoperatively, the localization information provided by NBS 6 is intended to be verified by direct cortical stimulation. NBS 6 is not intended to be used during a surgical procedure. NBS 6 is intended to be used by trained clinical professionals.
NEW!Post-operative Rehabilitation (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for the treatment of surgically induced new or worsening post-operative motor deficits of the upper limb as an adjunct therapy for motor rehabilitation in adult patients having undergone brain tumor surgery. NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of post-operative rehabilitation in the United States, for investigational use only.
Major Depressive Disorder (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for treatment of major depressive disorder (MDD) by targeting and delivering noninvasive repetitive TMS stimulation to the patient's dorsolateral prefrontal cortex.
Indications for use: NBS 6 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NBS 6 is intended to be use by trained clinical professionals.
Adolescent Major Depressive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21).
Obsessive-Compulsive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of adult patients suffering from obsessive-compulsive disorder (OCD).
Chronic Neuropathic Pain (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: In adult patients suffering from chronic unilateral neuropathic pain, NBS 6 is intended to provide electric field navigated noninvasive repetitive TMS stimulation as therapy to alleviate pain. NBS 6 is intended to be used by trained clinical professionals.
Indications for use: NBS 6 is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients. Nexstim NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of the treatment of chronic pain in the United States, for investigational use only.
Pre-procedural mapping (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for localization and assessment of the motor cortex and motor tract integrity for pre-procedural planning purposes. NBS 6 is intended to be used for localization and assessment of cortical areas of speech function for pre-procedural planning purposes.
Indications for use: NBS 6 is indicated for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus. NBS 6 provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. NBS 6 is indicated for noninvasive localizations of cortical areas that do not contain essential speech function. NBS 6 provides information that may be used in pre-surgical planning in patients undergoing brain surgery. Intraoperatively, the localization information provided by NBS 6 is intended to be verified by direct cortical stimulation. NBS 6 is not intended to be used during a surgical procedure. NBS 6 is intended to be used by trained clinical professionals.
NEW!Post-operative Rehabilitation (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for the treatment of surgically induced new or worsening post-operative motor deficits of the upper limb as an adjunct therapy for motor rehabilitation in adult patients having undergone brain tumor surgery. NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of post-operative rehabilitation in the United States, for investigational use only.
Major Depressive Disorder (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for treatment of major depressive disorder (MDD) by targeting and delivering noninvasive repetitive TMS stimulation to the patient's dorsolateral prefrontal cortex.
Indications for use: NBS 6 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NBS 6 is intended to be use by trained clinical professionals.
Adolescent Major Depressive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21).
Obsessive-Compulsive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of adult patients suffering from obsessive-compulsive disorder (OCD).
Chronic Neuropathic Pain (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: In adult patients suffering from chronic unilateral neuropathic pain, NBS 6 is intended to provide electric field navigated noninvasive repetitive TMS stimulation as therapy to alleviate pain. NBS 6 is intended to be used by trained clinical professionals.
Indications for use: NBS 6 is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients. Nexstim NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of the treatment of chronic pain in the United States, for investigational use only.
